Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
WITHDRAWN
NCT07537894
PHASE2/PHASE3

Perioperative Dexmedetomidine to Reduce Post-procedure Grief Following Second-trimester Dilation and Evacuation

Sponsor: Stanford University

View on ClinicalTrials.gov

Summary

People seeking second-trimester dilation and evacuation (D\&E) procedures are often facing profoundly challenging circumstances, including desired pregnancies complicated by fetal anomalies or demise, serious maternal health conditions, or changes in financial or relationship status. Although abortion regret is uncommon, the emotional burden surrounding these experiences is substantial: many patients experience significant grief and post-traumatic stress symptoms in the weeks to months following care. Perioperative interventions that decrease the body's stress response offer a promising opportunity to reduce downstream psychologic morbidity. Dexmedetomidine has been shown to reduce PTSD symptoms in other high-stress medical and surgical settings. The investigators are undertaking a randomized trial to evaluate whether perioperative administration of dexmedetomidine during second-trimester D\&E can reduce the frequency and severity of post-procedural grief, directly addressing an unmet need in patient-centered, trauma-informed abortion care.

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

0

Start Date

2026-07

Completion Date

2028-07

Last Updated

2026-07-17

Healthy Volunteers

No

Interventions

DRUG

Dexmedetomidine (IV) 0.5 mcg/kg

Infusion of dexmedetomidine 0.5ug/kg over 10 minutes at anesthesia induction

DRUG

Placebo

Saline infusion at equal volume to intervention arm

Locations (1)

Stanford Health Care

Palo Alto, California, United States